Fil LTD Exelixis, Inc. Transaction History

Fil LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$16.3 - $21.14 $2.07 Million - $2.69 Million	-127,060 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$17.95 - $25.56 $5.36 Million - $7.64 Million	-298,851 Reduced 70.17%	127,060 $2.32 Million
Q1 2021 May 14, 2021	SELL	$20.53 - $25.22 $2.14 Million - $2.63 Million	-104,271 Reduced 19.67%	425,911 $9.62 Million
Q4 2020 Feb 08, 2021	BUY	$18.39 - $24.8 $6.56 Million - $8.85 Million	356,688 Added 205.59%	530,182 $10.6 Million
Q3 2020 Nov 13, 2020	BUY	$20.67 - $26.94 $3,389 - $4,418	164 Added 0.09%	173,494 $4.24 Million
Q2 2020 Aug 13, 2020	SELL	$16.46 - $27.42 $13.7 Million - $22.9 Million	-833,800 Reduced 82.79%	173,330 $4.12 Million
Q1 2020 May 14, 2020	BUY	$14.46 - $21.8 $14.6 Million - $22 Million	1,007,130 New	1,007,130 $17.3 Million

502

243M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $10.9B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Fil LTD, based on Form 13F filings with the SEC.

Stay updated on Fil LTD with notifications on news.